Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis.
BACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy. METHODOLOGY AND PRINCIPAL FINDINGS: We systemat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3585408?pdf=render |
| _version_ | 1818126632132542464 |
|---|---|
| author | Jie-Ning Wang Shu Diao Yuan-Jun Tang An-Ji Hou Hai-Bo Yuan Yan Zheng Yu-Hao Zhou |
| author_facet | Jie-Ning Wang Shu Diao Yuan-Jun Tang An-Ji Hou Hai-Bo Yuan Yan Zheng Yu-Hao Zhou |
| author_sort | Jie-Ning Wang |
| collection | DOAJ |
| description | BACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy. METHODOLOGY AND PRINCIPAL FINDINGS: We systematically searched the Medline, Embase, and Cochrane Central Register of Controlled Trials databases and reference lists of articles and proceedings of major meetings for obtaining relevant literature. All eligible trials included ACS patients who received either i.c. administration of abciximab or i.v. therapy. The primary outcome was major cardiovascular events, and secondary outcomes included total mortality, reinfarction, and any possible adverse events. Of 660 identified studies, we included 9 trials reporting data on 3916 ACS patients. Overall, i.c. administration of abciximab resulted in 45% reduction in relative risk for major cardiovascular events (RR; 95% confidence interval [CI], 24-60%), 41% reduction in RR for reinfarction (95% CI, 7-63%), and 44% reduction in RR for congestive heart failure relative to i.v. therapy (95% CI, 8-66%); however, compared to i.v. therapy, i.c. administration of abciximab had no effect on total mortality (RR, 0.69; 95% CI, 0.45-1.07). No other significant differences were identified between the effect of i.c. abciximab administration and i.v. therapy. CONCLUSIONS/SIGNIFICANCE: I.c. administration of abciximab can reduce the risk of major cardiovascular events, reinfarction, and congestive heart failure when compared with i.v. therapy. |
| first_indexed | 2024-12-11T07:04:33Z |
| format | Article |
| id | doaj.art-8153f76207ad402caeb8ccd279b5972a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T07:04:33Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-8153f76207ad402caeb8ccd279b5972a2022-12-22T01:16:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0182e5807710.1371/journal.pone.0058077Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis.Jie-Ning WangShu DiaoYuan-Jun TangAn-Ji HouHai-Bo YuanYan ZhengYu-Hao ZhouBACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy. METHODOLOGY AND PRINCIPAL FINDINGS: We systematically searched the Medline, Embase, and Cochrane Central Register of Controlled Trials databases and reference lists of articles and proceedings of major meetings for obtaining relevant literature. All eligible trials included ACS patients who received either i.c. administration of abciximab or i.v. therapy. The primary outcome was major cardiovascular events, and secondary outcomes included total mortality, reinfarction, and any possible adverse events. Of 660 identified studies, we included 9 trials reporting data on 3916 ACS patients. Overall, i.c. administration of abciximab resulted in 45% reduction in relative risk for major cardiovascular events (RR; 95% confidence interval [CI], 24-60%), 41% reduction in RR for reinfarction (95% CI, 7-63%), and 44% reduction in RR for congestive heart failure relative to i.v. therapy (95% CI, 8-66%); however, compared to i.v. therapy, i.c. administration of abciximab had no effect on total mortality (RR, 0.69; 95% CI, 0.45-1.07). No other significant differences were identified between the effect of i.c. abciximab administration and i.v. therapy. CONCLUSIONS/SIGNIFICANCE: I.c. administration of abciximab can reduce the risk of major cardiovascular events, reinfarction, and congestive heart failure when compared with i.v. therapy.http://europepmc.org/articles/PMC3585408?pdf=render |
| spellingShingle | Jie-Ning Wang Shu Diao Yuan-Jun Tang An-Ji Hou Hai-Bo Yuan Yan Zheng Yu-Hao Zhou Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. PLoS ONE |
| title | Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. |
| title_full | Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. |
| title_fullStr | Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. |
| title_full_unstemmed | Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. |
| title_short | Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. |
| title_sort | intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome a meta analysis |
| url | http://europepmc.org/articles/PMC3585408?pdf=render |
| work_keys_str_mv | AT jieningwang intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis AT shudiao intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis AT yuanjuntang intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis AT anjihou intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis AT haiboyuan intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis AT yanzheng intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis AT yuhaozhou intracoronaryversusintravenousadministrationofabciximabinpatientswithacutecoronarysyndromeametaanalysis |